Literature DB >> 10591480

Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats.

T Kosasa1, Y Kuriya, Y Yamanishi.   

Abstract

Donepezil hydrochloride (donepezil), a potent and selective acetylcholinesterase inhibitor, has been developed for the treatment of Alzheimer's disease. We studied the effect of oral administration of this drug on the extracellular acetylcholine (ACh) concentration in the cerebral cortex of rats using microdialysis. We also observed fasciculation, a peripheral cholinergic sign induced by activation of neuromuscular transmission, after oral administration of the drug as an index of peripheral cholinergic activation. Other cholinesterase inhibitors, tacrine, ENA-713 and TAK-147, were used as reference drugs. Donepezil significantly and dose-dependently increased the extracellular ACh concentration in the rat cerebral cortex within the dose range of 2.5-10 mg/kg. Tacrine, ENA-713 and TAK-147 also elevated the extracellular concentration of ACh. The minimum effective doses of donepezil, tacrine, ENA-713 and TAK-147 were (< or = 2.5, 10, 10 and < or = 10 mg/kg, respectively. Donepezil produced fasciculation at doses of 2.5 mg/kg and above, with a dose-dependent increase in incidence and intensity. The reference compounds also induced fasciculation in a dose-dependent manner. The threshold doses of tacrine, ENA-713 and TAK-147 for fasciculation were 5, 2.5 and 2.5 mg/kg, respectively. The values of the ratio of the minimum effective dose for the ACh-increasing action to that for the fasciculation-producing action were: donepezil, < or = 1; tacrine, 2; ENA-713, 4; TAK-147, < or = 4. These results indicate that orally administered donepezil has a potent and selective activity on the central cholinergic system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10591480     DOI: 10.1254/jjp.81.216

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  5 in total

1.  Effects on cholinergic markers in rat brain and blood after short and prolonged administration of donepezil.

Authors:  Kristin Huse Haug; Inger Lise Bogen; Harald Osmundsen; Ivar Walaas; Frode Fonnum
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

2.  Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635.

Authors:  C Balducci; M Nurra; A Pietropoli; R Samanin; M Carli
Journal:  Psychopharmacology (Berl)       Date:  2003-03-05       Impact factor: 4.530

3.  Effect of a CNS-Sensitive Anticholinesterase Methane Sulfonyl Fluoride on Hippocampal Acetylcholine Release in Freely Moving Rats.

Authors:  Tamotsu Imanishi; Muhammad Mubarak Hossain; Tadahiko Suzuki; Ping Xu; Itaru Sato; Haruo Kobayashi
Journal:  Adv Pharmacol Sci       Date:  2012-01-29

4.  Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP).

Authors:  Hideyuki Sawada; Tomoko Oeda
Journal:  BMJ Open       Date:  2013-09-25       Impact factor: 2.692

5.  Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior.

Authors:  Alexander Hawlitschka; Carsten Holzmann; Andreas Wree; Veronica Antipova
Journal:  Toxins (Basel)       Date:  2018-09-11       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.